4-hydroxy-2-oxoglutarate metabolism in a mouse model of Primary Hyperoxaluria Type 3.

Xingsheng Li, Owen P Cunneely, Sonia Fargue, Kyle D Wood, Dean G Assimos, John Knight

Abstract read

In one paragraph

Article in Biochemistry and biophysics reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Normal urinary oxalate excretion in 4-hydroxy-2-oxo-glutarate aldolase 1 (HOGA1) deficient mice with AGT expression in peroxisomes and not in mitochondria.Biochimica et biophysica acta. Molecular basis of disease · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xingsheng LiDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.

Owen P CunneelyDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.

Sonia FargueDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.

Kyle D WoodDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.

Dean G AssimosDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.

John KnightDepartment of Urology, University of Alabama at Birmingham, Birmingham, AL, USA.

Funding

Hydroxyproline Dehydrogenase Inhibitors for the Treatment of Primary HyperoxaluriaR01DK137305 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI W TODD LOWTHER · 2024 to 2026

$2.0M

NIDDK NIH HHS R01 DK137305

6 · The paper itself

Abstract

Primary Hyperoxaluria Type 3 (PH3) results from 4-hydroxy-2-oxoglutarate (HOG) aldolase (HOGA) deficiency, which causes an increase in endogenous oxalate synthesis leading to calcium oxalate kidney stone disease. The mechanisms underlying HOG metabolism and increased oxalate synthesis in PH3 are not well understood. We used a

Indexed as

4-Hydroxy-2-oxoglutarate4-Hydroxy-2-oxoglutarate aldolaseHydroxyprolineKidney stonesOxalatePrimary hyperoxaluria type 3

Identifiers

PMID39040543

DOI10.1016/j.bbrep.2024.101765

PMCPMC11261398

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.